▶ GLP-1 / GLUCAGON DUAL AGONIST · SUBTOPIC · MECHANISM
GLP-1 / GLUCAGON DUAL AGONIST Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Dual GLP-1 and glucagon receptor agonist developed by the originator pharma sponsor as BI 456906. Combines incretin-driven glycemic control with glucagon-driven thermogenesis. Phase 3 SYNCHRONIZE program targets obesity and NASH simultaneously.
PHARMACOKINETIC HALF-LIFE
Reported half-life for GLP-1 / GLUCAGON DUAL AGONIST: ~7 days (once-weekly). Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
PRIMARY SEQUENCE
GLP-1 / GLUCAGON DUAL AGONIST is a defined sequence: Modified glucagon backbone with dual receptor selectivity. Synthesis proceeds via solid-phase peptide synthesis with HPLC-verified identity confirmation.
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with GIGARESEARCH evidence grades. Grades reflect study quality and replication, not clinical recommendation.
Le Roux 2024 Lancet Diabetes Endocrinol · placebo-subtracted weight loss 14.9% at 4.8 mg/wk in 46-week Phase 2.
Improvement in liver fat fraction + histology endpoints, supporting dedicated NASH Phase 3 program.
MECHANISM Q+A
▶ What is the GLP-1 / glucagon dual agonist?
the GLP-1 / glucagon dual agonist (BI 456906) is a once-weekly GLP-1/glucagon dual receptor agonist developed by the originator pharma sponsor and Zealand Pharma for obesity and NASH/MASH research.
▶ Why combine glucagon agonism with GLP-1?
Glucagon receptor activation increases hepatic lipolysis and energy expenditure; GLP-1 reduces appetite. The combination targets both intake and expenditure, theoretically producing greater fat-mass reduction than GLP-1 monotherapy.
CITED LITERATURE
- Le Roux CW, et al.. Glucagon and GLP-1 receptor dual agonist the GLP-1 / glucagon dual agonist for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol 2024. PMID 38219768. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19